Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T2000 is an investigational, proprietary formulation of sodium oxybate being developed by Sun Pharmaceutical Industries for the treatment of moderate to severe essential tremor. Sodium oxybate is a central nervous system depressant that acts as an agonist at the gamma-aminobutyric acid receptor type B (GABA-B) and the gamma-hydroxybutyrate (GHB) receptor. While sodium oxybate is traditionally approved for the treatment of narcolepsy and cataplexy, T2000 is being evaluated for its potential to reduce tremor amplitude and frequency in patients with essential tremor who have not responded adequately to first-line therapies. The drug is currently in Phase 2 clinical development, including long-term safety and efficacy studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on T2000.